RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All CDSCO (India) updates
CDSCO (India)
NOTICE
Manufacturing and marketing of unapproved drug product Sodium Hyaluronate Eye Drops 0.3% w/v
Published: 3/18/2026Detected: 3/19/2026

Summary preview

Clarifies the regulatory stance on the manufacturing and marketing of Sodium Hyaluronate Eye Drops 0.3% w/v, categorizing them as unapproved products under current law.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
ophthalmology
manufacturing
quality
safety
#Sodium Hyaluronate
#eye drops
#unapproved drugs
#manufacturing compliance
#quality assurance

Official Source Document
Source Verified

Access the original document directly from INDIA CDSCO.

View Official Document

More from CDSCO (India)

  • Indiscriminate use of painkillers (NSAIDs), antibiotics and associated risk of Chronic Kidney Disease9/22/2026
  • LIST OF REGISTRED BA-BE STUDY CENTRE & BIO-ANALYTICAL LABORATORY under NDCT Rules 20199/18/2026
  • Public Health alert against the use of unauthorised Cosmetics Products9/14/2026
  • 2026.09.08 G.S.R. 791(E)_Draft notification for amendment in the Drugs Rules 1945 regarding mandatory installation of CCTV surveillance system at sales premises9/8/2026
  • Drug Regulatory and Law Enforcement Agencies Intensify Coordinated Action Against Illegal Manufacture and Distribution of Misbranded Drugs9/5/2026

Get CDSCO (India) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.